PortfoliosLab logoPortfoliosLab logo
AYTU vs. FUL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AYTU vs. FUL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Aytu BioPharma, Inc. (AYTU) and H.B. Fuller Company (FUL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AYTU achieves a -11.92% return, which is significantly lower than FUL's 1.73% return.


AYTU

1D
1.78%
1M
-8.40%
YTD
-11.92%
6M
2.23%
1Y
14.50%
3Y*
12.70%
5Y*
-53.73%
10Y*

FUL

1D
0.25%
1M
-1.99%
YTD
1.73%
6M
4.84%
1Y
8.55%
3Y*
-1.57%
5Y*
-1.62%
10Y*
3.54%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AYTU vs. FUL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AYTU
Aytu BioPharma, Inc.
-11.92%52.94%-40.14%-24.87%-86.00%-77.42%-38.35%22.41%-98.22%-88.85%
FUL
H.B. Fuller Company
1.73%-10.46%-16.19%14.97%-10.59%57.84%2.15%22.42%-19.84%10.03%

Correlation

The correlation between AYTU and FUL is 0.10, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Feb 2, 2017

0.12

Fundamentals

Market Cap

AYTU:

$24.07M

FUL:

$3.33B

EPS

AYTU:

-$2.91

FUL:

$2.88

PS Ratio

AYTU:

0.47

FUL:

0.96

PB Ratio

AYTU:

0.68

FUL:

1.61

Total Revenue (TTM)

AYTU:

$56.60M

FUL:

$3.46B

Gross Profit (TTM)

AYTU:

$36.14M

FUL:

$1.11B

EBITDA (TTM)

AYTU:

-$27.34M

FUL:

$495.48M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AYTU vs. FUL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AYTU
AYTU Risk / Return Rank: 5151
Overall Rank
AYTU Sharpe Ratio Rank: 5252
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 4949
Sortino Ratio Rank
AYTU Omega Ratio Rank: 4949
Omega Ratio Rank
AYTU Calmar Ratio Rank: 5252
Calmar Ratio Rank
AYTU Martin Ratio Rank: 5353
Martin Ratio Rank

FUL
FUL Risk / Return Rank: 5050
Overall Rank
FUL Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
FUL Sortino Ratio Rank: 4848
Sortino Ratio Rank
FUL Omega Ratio Rank: 4444
Omega Ratio Rank
FUL Calmar Ratio Rank: 5050
Calmar Ratio Rank
FUL Martin Ratio Rank: 5454
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AYTU vs. FUL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Aytu BioPharma, Inc. (AYTU) and H.B. Fuller Company (FUL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AYTUFULDifference
Sharpe ratioReturn per unit of total volatility

+0.02

Sortino ratioReturn per unit of downside risk

+0.11

Omega ratioGain probability vs. loss probability

1.10

1.07

+0.02

Calmar ratioReturn relative to maximum drawdown

0.41

0.32

+0.09

Martin ratioReturn relative to average drawdown

0.97

0.98

-0.01

AYTU vs. FUL - Sharpe Ratio Comparison

The current AYTU Sharpe Ratio is 0.27, which is comparable to the FUL Sharpe Ratio of 0.25. The chart below compares the historical Sharpe Ratios of AYTU and FUL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


AYTUFULDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.27

0.25

+0.02

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.63

-0.06

-0.57

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.11

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.36

0.27

-0.63

Drawdowns

AYTU vs. FUL - Drawdown Comparison

The maximum AYTU drawdown since its inception was -100.00%, which is greater than FUL's maximum drawdown of -68.25%. Use the drawdown chart below to compare losses from any high point for AYTU and FUL.


Loading charts...

Drawdown Indicators


AYTUFULDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-68.25%

-31.75%

Max Drawdown (1Y)

Largest decline over 1 year

-35.47%

-26.97%

-8.50%

Max Drawdown (3Y)

Largest decline over 3 years

-70.24%

-43.45%

-26.79%

Max Drawdown (5Y)

Largest decline over 5 years

-99.12%

-43.45%

-55.67%

Max Drawdown (10Y)

Largest decline over 10 years

-56.29%

Current Drawdown

Current decline from peak

-100.00%

-28.49%

-71.51%

Average Drawdown

Average peak-to-trough decline

-95.15%

-18.76%

-76.39%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.92%

8.70%

+6.22%

Volatility

AYTU vs. FUL - Volatility Comparison

Aytu BioPharma, Inc. (AYTU) has a higher volatility of 14.09% compared to H.B. Fuller Company (FUL) at 11.03%. This indicates that AYTU's price experiences larger fluctuations and is considered to be riskier than FUL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AYTUFULDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.09%

11.03%

+3.06%

Volatility (6M)

Calculated over the trailing 6-month period

33.39%

26.42%

+6.97%

Volatility (1Y)

Calculated over the trailing 1-year period

55.06%

34.82%

+20.24%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.66%

29.38%

+56.28%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

188.20%

31.11%

+157.09%

Dividends

AYTU vs. FUL - Dividend Comparison

AYTU has not paid dividends to shareholders, while FUL's dividend yield for the trailing twelve months is around 1.58%.


PositionTTM20252024202320222021202020192018201720162015
AYTU
Aytu BioPharma, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
FUL
H.B. Fuller Company
1.58%1.56%1.29%0.99%1.03%0.82%1.25%1.23%1.44%1.10%1.14%1.40%

Financials

AYTU vs. FUL - Financials Comparison

This section allows you to compare key financial metrics between Aytu BioPharma, Inc. and H.B. Fuller Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20222023202420252026
12.41M
770.84M
(AYTU) Total Revenue
(FUL) Total Revenue
Values in USD except per share items

AYTU vs. FUL - Profitability Comparison

The chart below illustrates the profitability comparison between Aytu BioPharma, Inc. and H.B. Fuller Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
61.2%
31.3%
Portfolio components
AYTU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a gross profit of 7.60M and revenue of 12.41M. Therefore, the gross margin over that period was 61.2%.

FUL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, H.B. Fuller Company reported a gross profit of 240.99M and revenue of 770.84M. Therefore, the gross margin over that period was 31.3%.

AYTU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported an operating income of -4.06M and revenue of 12.41M, resulting in an operating margin of -32.8%.

FUL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, H.B. Fuller Company reported an operating income of 60.86M and revenue of 770.84M, resulting in an operating margin of 7.9%.

AYTU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a net income of -5.62M and revenue of 12.41M, resulting in a net margin of -45.3%.

FUL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, H.B. Fuller Company reported a net income of 21.05M and revenue of 770.84M, resulting in a net margin of 2.7%.


Frequently Asked Questions


AYTU and FUL have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AYTU has higher volatility (14.09%) compared to FUL (11.03%). In terms of maximum drawdown, AYTU dropped -100.00% vs FUL's -68.25%.

AYTU currently has the higher Sharpe Ratio (0.27 vs 0.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AYTU and FUL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer